SNH6, a new dual-action therapy, has the potential to restore mitochondria function and may ultimately be used to treat cardiomyopathyAn abnormal condition of the heart muscle. Occurs in some kinds of mitochondrial disease. in patients with Friedreich’s ataxiaImpaired coordination of voluntary muscle movements. Manifestations can include, among others, slurred speech, poor balance, unsteady walking, falling, and involuntary eye movements (nystagmus). Usual (FA), a mouse study found. The compound’s dual mechanism allows it to both reduce the buildup of iron and modulate levels of important mitochondrialRelated to the mitochondria. […]
Click here to view original web page at friedreichsataxianews.com
